sarepta gene therapy - Search News

News

Sarepta Will Resume Gene Therapy Shipments

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients, following a brief pause requested by regulators.

· 7h · on MSN

Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

Fierce Pharma · 17h

FDA launches probe into new Elevidys death as Sarepta, Roche stress gene therapy not at fault

3don MSN

Sarepta fails to win EU backing for muscle disorder gene therapy

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...

2don MSN

Two boys died after a gene therapy. This family won’t give up hope.

The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients died, the drug’s manufacturer halted dosing under pressure from the FDA.

MIT Technology Review3d

The deadly saga of the controversial gene therapy Elevidys

The drug, which was designed to treat Duchenne muscular dystrophy, has been linked to the deaths of two teenage boys.

STAT3d

Europe moves to reject embattled Duchenne muscular dystrophy gene therapy

European regulators said that a Duchenne gene therapy should not be approved, imperiling the treatment that is also facing ...

Investor's Business Daily on MSN4d

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies.

Sarepta stock plunged again Thursday on a report that the Food and Drug Administration will require additional clinical ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results